 CAMBRIDGE, Mass., Sept. 10, 2021 PRNewswire -- Synlogic, Inc. Nasdaq: SYBX, a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an investigational Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria HOX, during the American Urological Association AUA Annual Meeting, being held virtually September 10 13th. 